News and Events

Austin, Jan. 9, 2019 – Elligo Health Research, an integrated research organization, has acquired Protenium Clinical Research. Protenium, an established research group led by Robert Strzinek, Ph.D., D.O., conducts pharmaceutical studies in a broad range of therapeutic areas.

Dr. Strzinek has more than 15 years of clinical research experience and will now conduct research at his practice in partnership with Elligo. The acquisition brings the number of patients in Elligo’s Research Ready network to more than one million. As part of Elligo’s Goes Direct® approach, these patients will now have access to clinical research as a care option from their own trusted physician.

“Joining Elligo’s Dallas–Fort Worth Community of Research will ensure that we continue to provide the best clinical research opportunities to our patients and help us expand research opportunities across the region,” said Dr. Strzinek. “Our partnership allows us to focus on patient care while benefiting from Elligo’s research relationships and operational expertise.”

Dr. Strzinek has completed over 150 research studies and authored numerous journal articles covering several areas including endocrinology and women’s health. He and the Elligo team will continue to conduct research and support other community-based health care providers participating in research.

“The opportunity to leverage Dr. Strzinek’s highly experienced practice and integrated clinical operation in our Research Ready network and Communities of Research furthers our mission to bring together and empower health organizations and improve clinical trial access and efficiency,” said John Potthoff, Ph.D., CEO at Elligo. “We are delighted to welcome him, and his staff and patients to the Elligo family.”

About Elligo
Elligo Health Research, an integrated research organization, expands access to clinical research by bringing together health care data, community physicians and their patients. Only Elligo’s Goes Direct® approach and IntElligo Research Stack™ clinical technology — a complete standards-based technology solution — deliver better patients and improved real-time data through Elligo’s network of Research Ready sites within its Communities of Research. Learn more at elligodirect.com.

Austin, Texas, Sept. 27, 2018 – Elligo Health Research, an integrated research organization, has added Dan Pucci, MBA, as vice president of strategic partnerships, and Michael A. Ibara, Pharm.D., as vice president of data sciences, to its executive leadership team.

Pucci will lead Elligo’s strategic partnerships and new practice development group. Through this group, and in partnership with Elligo’s network management group, Pucci will develop key business relationships that grow and nurture Elligo’s network of Research Ready sites. In this role, he will directly support Elligo’s effort to bring together health care data with community physicians and their patients.

Pucci has a decade of experience building commercial and research partnerships with life sciences and health care insights organizations. Prior to Elligo, he helped develop and grow the point-of-care content, and payer and life sciences business units at Allscripts Healthcare Solutions.

Ibara, who has a record of innovation in the pharmaceutical industry and more than two decades of experience bringing together health care data and digital technologies in regulatory environments, most recently served as head of digital health care for the Clinical Data Interchange Standards Consortium (CDISC).

In his new role, Ibara will support the data sciences team as they apply analytical and algorithmic techniques to clinical data, improving patient matching, trend identification and reporting of insights to patients, investigators and sponsors. Ibara will also lead data-driven research projects for Elligo’s clients and provide subject matter expertise across all aspects of pharmacovigilance.

“Elligo has seen a lot of growth over the last several months,” said John Potthoff, Ph.D., CEO at Elligo. “Both Dan’s and Michael’s experience and respective strengths will keep our team at the forefront of the effort to bring clinical research and clinical care together to improve research study participation and trial quality across the board.”

About Elligo
Elligo Health Research, an integrated research organization, expands access to clinical research by bringing together health care data, community physicians and their patients. Only Elligo’s Goes Direct® approach and IntElligo Research Stack™ clinical technology — a complete standards-based technology solution — deliver better patients and improved real-time data through Elligo’s network of Research Ready sites within its Communities of Research. Learn more at elligodirect.com.

Austin, Texas, and Avon, Conn., August 14, 2018 – Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, announces its partnership with Women’s Health USA, a growing national network of women’s health, obstetrics and gynecology practices. The partnership will expand Elligo’s Research Ready™ network to include Women’s Health USA health care providers, allowing their patients to access clinical research as a care option from their trusted physician.

With more than 600 physician partners practicing in seven states, this partnership will make it easier for Women’s Health USA’s patients to participate in clinical research. “We can make a bigger impact on the future of medicine together,” said Chad Moore, president of Elligo. “With our partners’ help, not only are we bringing clinical research direct to clinical health care, but we are matching more participants to clinical trials than ever before.”

Elligo’s Goes Direct® approach provides physician practices with the infrastructure, technology and expertise necessary to conduct clinical research. “Our goal is to help our women’s health practices leverage the best tools for the best outcomes,” said Goran Dragolovic, CEO at Women’s Health USA. “Partnering with Elligo allows our providers to maintain the highest standards for quality, patient-focused care, while adding innovative, state-of-the-art treatment options for their patients.”

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About Women’s Health USA
Women’s Health USA currently partners with OB/GYN, in vitro fertilization, and other specialty women’s health practices in seven states to implement growth strategies, payer engagement, revenue cycle management, EMR support, financial and human resource management, merger and acquisition support, ancillary services development, marketing and risk management services. With more than 600 physician partners, its unique and successful partnership model enables physicians and physician groups to maintain their independence, while leveraging the resources of a national organization.

Austin, Texas, July 10, 2018 — Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, has appointed former founder, executive chairman and CEO of Greenway Health, Wyche T. “Tee” Green III, as a director. Green has been a force behind the health care information technology (IT) movement since he co-founded Greenway Medical Technologies (now Greenway Health) in 1998.

Bridging the gap between clinical research and physician practices is the focus of Elligo’s approach. Green, who has dedicated nearly two decades to integrating and streamlining clinical, financial, administrative and patient-facing health care information systems, will provide Elligo with invaluable insight. While at Greenway, he invested in bringing clinical trials to thousands of providers and patients with a single mission: to improve health.

“We are honored and excited that Tee Green has accepted our invitation to join the board of directors,” said John Potthoff, Ph.D., CEO of Elligo. “This is a great leap for Elligo. We look forward to working with Tee as we refine our information systems and seek out new ways to make life-changing research accessible to all.”

“I’ve dedicated my career to improving population health by building a smarter, more sustainable health care system with advanced, integrated, information services,” said Green. “Increasing connectivity for the greater good is my passion, so when I realized Elligo was working to connect researchers with patients, I was intrigued.”

In addition to his work in health care IT and health care reform, Green has served on several additional boards ranging from the Auburn University Research Advisory Board to West Georgia Habitat for Humanity.

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Austin, Texas, and Arlington, Va., June 26, 2018 – Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, has partnered with HealthiVibe, an organization that gathers patient insights to optimize clinical trials. The goal of the partnership is to bring the patient to the center of the clinical trial experience. Elligo will now offer HealthiVibe’s HealthiPerspectives™ end-to-end patient survey and industry benchmarking platform to its network of sites.

The HealthiPerspectives platform is a first-of-its-kind, sustainable, repeatable and scalable process for leveraging patient feedback during a clinical trial. Through its cloud-based, web survey interface, HealthiPerspectives will gather the patient-sourced data needed by Elligo to make real-time modifications to the way clinical trials are conducted, drawing on quantifiable insights to increase enrollment and retention and deliver more cost-effective studies.

“Partnering with Elligo enables us to continue to expand our offering,” said Jennifer Kelly, vice president at HealthiVibe. “Aligning with Elligo will increase our industry benchmarking database, providing valuable patient insights that will ultimately enhance our mission of making the patient voice an integral part of the clinical trial development process.”

“Elligo’s mission is to provide all patients and physicians with the opportunity to participate in clinical trials,” said Deirdre BeVard, chief development officer of Elligo Health Research. ”We want to optimize that experience for our research sites and their patients. This partnership and the subsequent data will help us continue to improve our offering and the patient experience and ultimately move more products to market faster.”

HealthiPerspectives has been implemented by large and small biopharmaceutical companies in more than 180 studies, spanning more than 30 countries and representing dozens of indications. HealthiPerspectives supports more than 200 different languages accessible from any internet-enabled device.

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

About HealthiVibe
HealthiVibe offers an evidence-based process for companies to assess patient insights at every stage of the pharmaceutical project lifecycle: from clinical trial design through post-approval activities and research. We offer full-service patient initiatives, with a focus on patient insights and communication, to help biopharmaceutical companies create more patient-centered programs. Learn more at HealthiVibe.com.

Austin, Texas, and Raleigh, N.C., June 21, 2018 — Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Elligo Health Research, the only platform that brings clinical research direct to clinical health care, are entering a strategic collaboration to mobilize a system of accelerated research to reach real-world patients. Both companies share a vision to evolve the clinical trial paradigm to speed the delivery of biopharmaceutical therapies to market.

Syneos Health is a top three Contract Research Organization (CRO) that combines comprehensive and integrated outsourcing solutions for both clinical development and commercialization. Elligo Health Research deploys an approach that improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients.

Applying its Goes Direct^® approach, Elligo identifies patients for clinical trials using electronic health records and then provides their physicians with the infrastructure to conduct the research in their own practices. This platform enables research at practices that historically would not have had the infrastructure to conduct clinical research. Syneos Health will collaborate with Elligo to pilot new ways of quickly finding patients to enlist them in clinical trial research.

The collaboration will seek to build a centrally managed infrastructure and regulatory research system around physicians and patients who have not typically been accessible in traditional sites. This could include deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden and focusing the experience around the patient.

The ability to bring clinical research to underrepresented populations through community medical practices, evolving from a location-bound approach, to a centrally managed systemic approach, redefines the clinical trial site footprint. This effort should improve quality, reduce timelines and save costs.

“Our biopharma acceleration model is designed to completely surround the patient, caregiver or any stakeholder with the most relevant solutions to make the clinical trial process easier and more accessible. Our collaboration with Elligo allows us to do just that,” said Alistair Macdonald, chief executive officer, Syneos Health. “By leveraging data, technology and trusted physician relationships, we believe we can radically reduce enrollment times and impact health outcomes on behalf of our customers.”

“We are thrilled to collaborate with Syneos Health to create a system of accelerated research that expands our vision of engaging the patient and physician in clinical research,” said John Potthoff, Ph.D., chief executive officer, Elligo. “Not only are we maximizing clinical trial process efficiencies, we’re transforming the clinical trial paradigm with deeper insights and more actionable real-world evidence.”

To learn more about how Syneos Health and Elligo are advancing clinical research, visit syneoshealth.com and elligodirect.com. Also, sign up to receive information about the 2019 Bridging Clinical Research and Clinical Health Care Collaborative, an event sponsored by Syneos Health and Elligo to strengthen the connection between clinical research and health care.

About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life^® visit syneoshealth.com.

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct^® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the integration of the Company’s business with the business of inVentiv Health and its operation of the combined business following the closing of the Merger; the Company’s ability to maintain or generate new business awards; the Company’s ability to increase its market share, grow its business, and execute its growth strategies; the Company’s backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; the impact of adoption of the new accounting standard of recognizing revenue from customers; the impact of the Tax Act; the Company’s ability to adequately price its contracts and not overrun cost estimates; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; fluctuations in the Company’s financial results; reliance on key personnel; customer or therapeutic area concentration; and the other risk factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and other SEC filings, copies of which are available free of charge on the Company’s website at investor.syneoshealth.com. Syneos Health assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Austin, Texas, June 19, 2018 — Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, announces that Flatiron Health and the University of Chicago have agreed to act as data partners in a federal project led by the FDA to develop and pilot a common data architecture. This common architecture will serve as the intermediary between various data sources, thereby streamlining patient-centered research using de-identified or aggregated data from the delivery of health care in routine clinical settings.

Elligo is leading an effort to test the FDA harmonization model, a part of the common data architecture. Its partners, using a variety of electronic health record systems, will provide de-identified or aggregated datasets for the safety assessment of new oncology therapies.

“Our goal at Elligo is not just to facilitate research,” said John Potthoff, PhD, CEO of Elligo Health Research. “We embrace the opportunity to bring these companies together to work toward better data usability and patient outcomes.”

“Clinical research drives progress in oncology,” said Sam Volchenboum, MD, PhD, MS, associate professor of pediatrics and the director of the Center for Research Informatics at the University of Chicago Medicine. “This project will speed the conversion of de-identified research study data to make it more useful for the development of much-needed therapies.”

“Our electronic health record (EHR) systems are specifically designed for oncology providers and patients,” said Amy Abernethy, MD, PhD, chief medical officer and chief scientific officer, Flatiron Health. “By participating in this effort, we hope to advance standards that make the data more accessible for researchers to analyze and ultimately accelerate the development of cancer therapies.”

Mitra Rocca, the FDA’s associate director of medical informatics and the FDA lead on the harmonization project, will chair a session that covers the use of real-world data, including EHR data, on Tuesday, June 26, at the Drug Information Association (DIA) 2018 Global Annual Meeting in Boston.

 

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Austin, Texas, May 24, 2018 — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has acquired ePatientFinder’s Clinical Trial Exchange technology platform and referring practice network, which is the largest of its kind.

This acquisition will enhance Elligo’s trial matching process by incorporating ePatientFinder’s technology platform. Using this platform, Elligo will streamline patient identification and feasibility through automation using electronic health record (EHR) data within Elligo’s network of providers.

“We believe this is an important strategic opportunity for Elligo to expand our technology and network growth capabilities,” said John Potthoff, PhD, CEO of Elligo Health Research. “ePatientFinder provides a technology platform and partnership ecosystem that will enable us to automate our EHR data analytics capabilities and expand our network of Research Ready™ sites to further benefit physicians, patients and sponsors.”

Elligo implements its Goes Direct^® approach to provide physicians with the personnel, procedures, technology and infrastructure to conduct trials in Research Ready™ sites. This makes clinical trials more efficient and cost-effective, allowing patients to gain access to treatment options, enabling physicians to avoid the expenditure and effort of managing in-house infrastructure, and making it easier for sponsors to bring new therapies to market faster.

About Elligo
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct^® approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Austin, Texas, May 15, 2018 — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has launched a Research Ready™ program for physician practices interested in becoming a study site. Through the program, health care providers are able to offer clinical research studies as a care option to their patients. As a result, patient participation and retention rates increase, contributing to a more diverse population of patients and subsequently enabling clinical research organizations (CROs) and sponsors to get their studies up and running faster.

The Research Ready™ program is part of Elligo’s Goes Direct^® approach, which provides a larger patient pool, more randomizations and better retention by making clinical research studies accessible to physicians and their patients. Through the program, physician practices are evaluated on a number of study-related components and are provided the technology, the infrastructure and a clinical coordinator to perform trials.

“We know patient diversification is important for our trial sponsors and CROs,” said John Potthoff, Ph.D., CEO of Elligo. “We make it easier for more patients to participate in trials through their own trusted physician. And, not only are our sites benefiting from the infrastructure support, but our sponsors and CROs are getting quality study data from community practice researchers.”

Every research site conducting research with Elligo has received the Research Ready™ designation. Currently, Elligo has more than 200 physician partners — with specialization in women’s health, gastroenterology, urology and pain management indications.

About Elligo Health Research
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct^® approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.

Austin, Texas, March 20, 2018 — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.

“In a short time Elligo has clearly shown that their approach improves access to clinical trials,” said John Crumpler, general partner at Hatteras Venture Partners. “We believe they will build on their current successes and continue to drive positive changes in the health care industry.”

“Our programs speak specifically to the medical practices that are hesitant to perform research in their offices due to lack of resources and infrastructure,” said John Potthoff, Ph.D., CEO of Elligo. “The new funding will help us expand our services and not only make research studies more accessible to physician sites but also streamline data collection and submission processes.”

“We look for opportunities to support entrepreneurs who excel within their industries,” said Allen Moseley, managing general partner at Noro-Moseley Partners. “Elligo’s team has the drive to effect change and the expertise to develop robust processes and technologies to significantly improve the clinical trial process.”

“The investment will enable us to accelerate expansion of our network of physicians and refine our technology platform to improve study efficiency,” said Chad Moore, president of Elligo. “And, every day we are one step — one study, one patient, one physician — closer to fulfilling our mission of improving clinical research and bringing new treatments to market faster by making it easier for physicians and patients to participate.”

 

About Elligo
Elligo Health Research offers the only platform that brings clinical research to the clinic, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Elligo Goes Direct^® with an approach that uses electronic health records and other health data to identify real-world patients and physicians for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.